Immunohistochemical expression of the p53, mdm2, p21/Waf-1, Rb, p16, Ki67, Cyclin D1, Cyclin A and Cyclin B1 proteins and apoptotic index in T-cell lymphomas

Histology and Histopathology

Volumn 16, Issue 2, 2001, Pages 377-386

  Kanavaros, P ^a   Bai, M ^a   Stefanaki, K ^a   Poussias, G ^a   Rontogianni, D ^a   Zioga, E ^a   Gorgoulis, V ^a   Agnantis, N J ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Apoptosis; Cell cycle proteins; Immunohistochemistry; T cell lymphomas

Indexed keywords

CYCLIN A; CYCLIN B1; CYCLIN D1; KI 67 ANTIGEN; PROTEIN MDM2; PROTEIN P16; PROTEIN P21; PROTEIN P53;

APOPTOSIS; ARTICLE; CELL CYCLE PARAMETERS; COMPARATIVE STUDY; CONTROLLED STUDY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE; LYMPHOBLASTOID CELL; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MYCOSIS FUNGOIDES; NICK END LABELING; PATHOGENESIS; PERIPHERAL LYMPHOCYTE; PROTEIN EXPRESSION; T CELL LYMPHOMA; TUMOR CELL;

ADENOVIRUS E1A PROTEINS; APOPTOSIS; CARRIER PROTEINS; CELL CYCLE PROTEINS; CYCLIN A; CYCLIN B; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; KI-67 ANTIGEN; LYMPHOMA, LYMPHOBLASTIC; LYMPHOMA, T-CELL, PERIPHERAL; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; REPRESSOR PROTEINS; STATISTICS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0035070239     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Frequent methylation silencing of p15 (INK4b) (MTS1) and p16 (INK4a) (MTS2) in B and T-cell lymphomas
2. High levels of p53 protein expression do not correlate with p53 gene mutations in anaplastic large cell lymphoma
3. p21/WAF1 cyclin-kinase inhibitor expression in no-Hodgkin's lymphomas: A potential marker of p53 tumor-suppressor gene function
4. Mutations of cell regulators
5. Multiple pathways control cell growth and transformation: Overlapping and independent activities of p53 and p21
6. Prognostic significance of proliferative and apoptotic fractions in low grade follicle center cell-derived non-Hodgkin's lymphomas
7. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells
8. The accumulation of p53 abnormality is associated with progression of mucosa-associated lymphoid tissue lymphoma
9. Positive correlation between apoptotic and proliferative indices in gastrointestinal lymphoma of mucosa-associated lymphoid tissue
10. Loss of tumor suppressor p16 gene expression in high grade but not in low grade non-Hodgkin's lymphomas
11. Cell cycle
12. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Group d' Etude des Lymphomes de l'Adulte (GELA)
13. Investigtion of the Rb-1 tumour suppressor gene in a United Kingdom series of non-Hodgkin's lymphomas
14. Inactivation of multiple tumor-suppressor genes involved in negative regulation of the cell cycle, MTS1/p16(INK4A)/CDKN2, MTS2/p15 (INK4B), p53 and Rb genes in primary lymphoid malignancies
15. Revised European-American classification of lymphoid neoplasms. A proposal from the International Lymphoma Study Group
16. Mdm2 promotes the rapid degradation of p53
17. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies
18. Rb regulates the stability and the apoptotic function of p53 via mdm2
19. Molecular characterization of CD30+anaplastic large-cell lymphoma. High frequency of c-myc protooncogene activation
20. Expression of retinoblastoma gene product in mantle cell lymphomas. Correlation with cyclin D1 (PRAD1/CCND1) mRNA levels and proliferative activity
21. Mycosis fungoides: Expression of p53, bcl-2 and PCNA proteins and absence of asseciation with Epstein-Barr virus
22. Expression of p53, p21/waf-1, bcl-2, bax, Rb and Ki-67 proteins in Hodgkin's lymphomas
23. Correlation between apoptosis, proliferation and bcl-2 expression in malignant non-Hodgkin's lymphomas
24. Regulation of p53 stability by mdm2
25. New functional activities for the p21 family of CDK inhibitors
26. p53 protein expression in cutaneous T-cell lymphomas
27. Expression of p34(cdc2) and cyclins A and B compared to other proliferative features of non-Hodgkin's lymphomas: A multivariate cluster analysis
28. Role of the p16 tumor suppressor gene in cancer
29. Human non-Hodfkin's lymphomas overexpress a wild-type form of p53 which is a functional transcriptional activator of the cyclin-dependent kinase inhibitor p21
30. Mdm2 expression in lymphoid cell and reactive and neoplastic lymphoid tissue. Comparative study with p53 expression
31. Hypermethylation of α 5′CpG island of p16 is a frequent event in non-Hodgkin's lymphoma
32. Retinoblastoma (Rb) gene product expression in lymphomas. Correlation with Ki67 growth faction
33. Post-thymic T-cell lymphomas frequently overexpress p53 protein but infrequently exhibit p53 gene mutations
34. Involvement of CDKN2 (p16 INK4A/MTS1) and p15 INK4B/MTS2 in human leukemias and lymphomas
35. Expression of p53 and retinoblastoma gene expression in high-grade nodal peripheral T-cell lymphomas: Immunohistochemical and molecular findings suggesting different pathogenetic pathways and possible clinical implications
36. P16 INK4A gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas
37. A model for p53-induced apoptosis
38. The p53 pathway
39. Structure and function of p53 in normal cells and their aberrations in cancer cells: Projection on the hematologic cell lineages
40. p53 mutation is associated with progression in follicular lymphomas
41. Why is p53 protein stabilized in neoplasia? Some answers but many more questions?
42. Immunodetection of apoptosis-regulating proteins in lymphomas from patients with and without human immunodeficiency virus infection
43. Role of the retinoblastoma protein in the pathogenesis of human cancer
44. Role of cyclin-dependent kinase 4 and 6 inhibitor gene family p15 p16, p18 and p19 in leukemias and lymphoma
45. Expression of p53, mdm2 and p21/waf-1 proteins in non-Hodgkin's lymphomas
46. CDKN2 (MTS1/p161NK4A) gene alterations in hematological malignancies
47. p21WAF1/CIP1 and mdm2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: A p53+, mdm2, p21- immunophenotype associated with missense p53 mutations
48. Loss of p16/INK4A protein expression in non-Hodgkin's lymphomas is a frequent finding associated with tumor progression
49. The retinoblastoma protein and cell cycle control
50. Altered expression of retinoblastoma gene product in human high-grade non-Hodgkin's lymphomas
51. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma
52. Interaction between the retinoblastoma protein and the oncoprotein MDM2
53. Abnormalities of retinoblastoma gene expression in hematological malignancies